Cargando…

Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?

BACKGROUND: Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC). METHODS: Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Menghan, Jia, Nan, Huang, Feifei, Liu, Xiaoxia, Zhao, Yuqing, Tao, Xiang, Jiang, Wei, Li, Qin, Feng, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654059/
https://www.ncbi.nlm.nih.gov/pubmed/29061125
http://dx.doi.org/10.1186/s12885-017-3671-0
_version_ 1783273335159783424
author Zhu, Menghan
Jia, Nan
Huang, Feifei
Liu, Xiaoxia
Zhao, Yuqing
Tao, Xiang
Jiang, Wei
Li, Qin
Feng, Weiwei
author_facet Zhu, Menghan
Jia, Nan
Huang, Feifei
Liu, Xiaoxia
Zhao, Yuqing
Tao, Xiang
Jiang, Wei
Li, Qin
Feng, Weiwei
author_sort Zhu, Menghan
collection PubMed
description BACKGROUND: Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC). METHODS: Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter ≥ 2 cm and 818 low-risk patients with grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter < 2 cm were enrolled in this study. The rate and risk factors of node metastasis were evaluated and compared between the two risk groups. Survival data were analyzed in patients with intermediate-risk EEC with or without lymphadenectomy. RESULTS: In all, 624 of 1009 (61.8%) patients with intermediate-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 1.9% (12/624), whereas 394 of 818 (48.2%) patients with low-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 0.3% (1/394) (p = 0.021). Notably, intermediate-risk EEC patients with a microcystic, elongated and fragmented (MELF) pattern of invasion, lymphatic vascular space invasion (LVSI), diffuse lesions, or lesions located in the cornua were more likely to have node metastasis. The 5-year overall cancer-related survival and the recurrence-free survival rates of the 742 intermediate-risk EEC patients who were followed for more than 3 years were 99.4% and 94.7%, respectively. In intermediate-risk group, 6 patients (6/443, 1.4%) with lymphadenectomy and 9 patients (9/299, 3.0%) without lymphadenectomy recurred, with a mean recurrence time of 38.3 and 18.7 months respectively. The five-year overall and recurrence-free survival rates of intermediate-risk patients with and without lymphadenectomy were similar (100% vs 98.9%, p = 0.351; 95.2% vs 93.3%, p = 0.464). CONCLUSION: Patients with intermediate-risk EEC have low nodal metastasis rate and a favorable outcome whether lymphadenectomy is performed or not. Omission of lymphadenectomy may be a reasonable option in the surgical management of patients with intermediate-risk EEC.
format Online
Article
Text
id pubmed-5654059
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56540592017-10-26 Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? Zhu, Menghan Jia, Nan Huang, Feifei Liu, Xiaoxia Zhao, Yuqing Tao, Xiang Jiang, Wei Li, Qin Feng, Weiwei BMC Cancer Research Article BACKGROUND: Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC). METHODS: Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter ≥ 2 cm and 818 low-risk patients with grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter < 2 cm were enrolled in this study. The rate and risk factors of node metastasis were evaluated and compared between the two risk groups. Survival data were analyzed in patients with intermediate-risk EEC with or without lymphadenectomy. RESULTS: In all, 624 of 1009 (61.8%) patients with intermediate-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 1.9% (12/624), whereas 394 of 818 (48.2%) patients with low-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 0.3% (1/394) (p = 0.021). Notably, intermediate-risk EEC patients with a microcystic, elongated and fragmented (MELF) pattern of invasion, lymphatic vascular space invasion (LVSI), diffuse lesions, or lesions located in the cornua were more likely to have node metastasis. The 5-year overall cancer-related survival and the recurrence-free survival rates of the 742 intermediate-risk EEC patients who were followed for more than 3 years were 99.4% and 94.7%, respectively. In intermediate-risk group, 6 patients (6/443, 1.4%) with lymphadenectomy and 9 patients (9/299, 3.0%) without lymphadenectomy recurred, with a mean recurrence time of 38.3 and 18.7 months respectively. The five-year overall and recurrence-free survival rates of intermediate-risk patients with and without lymphadenectomy were similar (100% vs 98.9%, p = 0.351; 95.2% vs 93.3%, p = 0.464). CONCLUSION: Patients with intermediate-risk EEC have low nodal metastasis rate and a favorable outcome whether lymphadenectomy is performed or not. Omission of lymphadenectomy may be a reasonable option in the surgical management of patients with intermediate-risk EEC. BioMed Central 2017-10-23 /pmc/articles/PMC5654059/ /pubmed/29061125 http://dx.doi.org/10.1186/s12885-017-3671-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhu, Menghan
Jia, Nan
Huang, Feifei
Liu, Xiaoxia
Zhao, Yuqing
Tao, Xiang
Jiang, Wei
Li, Qin
Feng, Weiwei
Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
title Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
title_full Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
title_fullStr Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
title_full_unstemmed Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
title_short Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
title_sort whether intermediate-risk stage 1a, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654059/
https://www.ncbi.nlm.nih.gov/pubmed/29061125
http://dx.doi.org/10.1186/s12885-017-3671-0
work_keys_str_mv AT zhumenghan whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT jianan whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT huangfeifei whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT liuxiaoxia whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT zhaoyuqing whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT taoxiang whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT jiangwei whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT liqin whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection
AT fengweiwei whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection